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Summary 
Earlier studies revealed that human interleukin 6 (IL-6) contains recognition sites for the hepatitis 
B virus (HBV) envelope (env) protein, and that IL-6 and anti-Ib6 antibodies, respectively, inhibited 
the interaction of ceils expressing a receptor for HBV with the preS(21-47)  segment of the HBV 
env protein, encompassing the complementary attachment site for IL-6. This suggested that IL-6 
mediates HBV-cell interactions. We report that: (a) Chinese hamster ovary cells transfected with 
human IL-6 cDNA  and Spodoptera frugiperda ovarian  insect cells infected with recombinant 
baculovirus carrying human Ib6 cDNA expressed receptors for the preS(21-47)  region of the 
HBV env protein, indicating that expression of IL-6 on the surface of calls is sufficient to endow 
them with receptors for HBV. (b) Among peptides covering the entire sequence of human IL-6 
and the corresponding antipeptide antibodies, the peptide Ib6135-66] and anti-Ib6135-66] most 
effectively inhibited the interaction between human hepatoma HepG2 cells and the preS(21-47) 
ligand, suggesting that this region of the human IL-6 sequence encompasses a binding site for 
the HBV env protein. (c) Studies with replacement set peptides from the preS(21-47)  sequence 
indicated that residues 21-25, 28, 31, 33-35, 39, and 43-45 can be replaced by alanine (serine) 
residues, while all the other residues are essential for maintaining the cell receptor/Ib6 binding 
activity.  Further delineation of complementary sites on Ib6 and on the HBV env protein may 
contribute to the design of compounds inhibiting HBV replication. 
H 
epatitis B virus (HBV) 1 is a major human pathogen 
implicated in primary hepatocarcinoma. The envelope 
(env) of the virus consists of three related proteins (S, M, 
and L) that are all products of a single env gene. These pro- 
teins share a common 226-residue  COOH-terminal amino 
acid  sequence  (S  protein).  M  protein  has  an  additional 
55-amino acid sequence located at the NH2 terminus (preS2 
sequence). L protein differs from M protein by an additional 
NHz-terminal 108- or 119-amino acid sequence designated 
as preS1. A segment of the preS1 sequence encompassing amino 
acid residues  21-47 is involved in the attachment of HBV 
to human hepatoma HepG2 cells (1) and to isolated human 
liver plasma membranes (2--4). The presence of receptors for 
the preS(21-47) region of the HBV env protein was demon- 
strated also on cells of nonhepatic origin, including PBL (5, 
6), representing, in addition to the liver, target cells for HBV 
(7-9). 
The preS(21-47)  region of the HBV env protein encore- 
1 Abbreviations used in thispaper: env, envelope; HBsAg, hepatitis B surface 
antigen; HBV,  hepatitis B  virus; PI-PLC, phosphatidylinositol-specific 
phospholipase C. 
passes a binding site for Ib6 (6). The following findings in- 
dicated that cell-associated Ib6 mediates the interaction be- 
tween the preS1 region of the HBV env proteins and ceils 
of hepatic or extrahepatic origin: (a) this interaction was in- 
hibited by Ib6 and by anti-IL-6 antibodies;  (b) stimulation 
of T cells and PBMC with Con A and LPS, respectively, in- 
duced the production of both IL6 and of recognition sites 
for the preS1 region of the HBV env protein; and (c) exposure 
of Ib6-producing cells to phosphatidylinositol-specific  phos- 
pholipase C  (PI-PLC)  or to low pH resulted in the release 
of cell-associated  IL-6 and in reduced cell binding to the 
preSl(21-47) ligand (6).  These results suggested that cell- 
associated Ib6 either represented a cell surface receptor for 
HBV or a constituent of a multicomponent receptor com- 
plex.  This  report  provides direct  evidence  that  cell  sur- 
face-associated II.-6 is sufficient to endow cells with binding 
activity for the preS1 region of the HBV env protein by demon- 
strating that nonhuman cells transfected  with human Ib6 
cDNA acquired receptors for HBV. Furthermore, regions on 
the IL-6 protein essential for recognition of the preS(21--47) 
ligand were delineated, and amino acid residues within the 
preS(21-47)  region essential for cell receptor binding were 
identified. 
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Cells Extrressing Human 11,6.  The following cell lines were used: 
human HepG2 hepatoma cells; Chinese hamster ovary (CHO) cells 
transfected with IL-6 cDNA (CHO-Ib6;  obtained from Sandoz 
Technology Ltd., Basel, Switzerland through the courtesy of the 
Genetics Institute, Cambridge, MA); and Spodopterafrugiperda SD 
ovarian cells infected with recombinant baculovirus carrying Ib6 
cDNA (B-Ib6 cells). The recombinant baculovirus was prepared 
by Invitrogen Corporation (San Diego, CA) as follows. Escherichia 
coli MC1061  containing phsmid pCSF309 carrying IL-6 cDNA 
(67153; American Type Cuhure Collection, Rockville, MD) was 
grown for large scale preparation of the plasmid DNA (10). The 
plasmid was purified by equilibrium centrifugation in CsCl-ethidium 
bromide  gradients.  The isolated  plasmid  DNA  as  well  as  the 
pVL1392 transfer vector were digested with the restriction enzyme 
EcoRI. The pVL1392 DNA was subsequently treated with alka- 
line phosphatase to prevent self-ligation  of the compatible EcoRI 
ends.  The EcoRI-cut plasmid  pCSF309 and the EcoRI-cut and 
phosphatase-treated  transfer vector pVL1392 were subsequently sub- 
jected to electrophoresis in a low-melting point agarose gel to pu- 
rify the 1.16-kb fragment containing IL-6 cDNA and the vector 
DNA,  respectively.  The respective  DNA fragments were recov- 
ered from the gel and ligated overnight. Chemically competent 
DHI~F' E. coli  cells were transformed with the ligated DNA. Colo- 
nies containing the desired  clone were identified by performing 
small-scale plasmid preparations and by EcoRI and AccI restric- 
tion digests to check for appropriate inserts and their orientation, 
respectively.  Positive colonies were selected and grown in 20-ml 
cultures from which plasmid DNA was prepared by purification 
on columns (Qiagen, Inc., Chatsworth, CA). The purified phsrnid 
DNA was used to transfect Sf9 insect cells along with linearized 
wild-type baculovirus DNA  following the Invitrogen MaxBac 
manual (Invitrogen Corporation). Recombinant baculovirus pro- 
duced by the transfected cells was purified and checked for purity 
by the PCR. High titer recombinant baculovirus stocks were pre- 
pared and used to infect SD cells. For studies on the surface expres- 
sion of IL-6, Sf9 cells were infected at a multiplicity of infection 
corresponding to 5. The infected cells (B-Ib6 ceils) were analyzed 
for expression of IL-6 48-72 h after infection. Uninfected Sf9 ceUs, 
Sf9 cells infected with wild-type baculovirus, and with recombinant 
baculovirus containing cDNA for the glucocorticoid binding pro- 
tein, respectively,  were used in control experiments. 
Peptide Synthesis.  Peptides  from the preS region of the HBV 
env protein, preS(12-32), preS(12-47), and preS(21--47), were syn- 
thesized and linked to cellulose as described before (1, 5, 6). Replace- 
ment setpeptides from the preS(21-47) sequence were synthesized 
on a multiple-peptide synthesizer (350 MPS; Advanced ChemTech, 
Louisville, KY) using 1,3-diisopropylcarbodiimide  and 1-hydroxy- 
benzotriazole activation in a 9-fluorenyl-methoxycarbonyl  (Fmoc)- 
mediated synthesis.  The peptides were cleaved off the resin  by 
TFA/thioanisole/ethanedithiol/anisole  (90:5:3:2)  for  4  h.  The 
peptide-resin mixtures were freeze dried and the peptides were ex- 
tracted from the resin with 20% acetic acid. Each of the peptides 
was purified on a C18 reverse-phase column with a linear 0.1% 
TFA/H20-100% acetonitrile  gradient.  Fractions corresponding to 
the major peak of absorbance at 214 nm were lyophilized and used 
for the experiments described below.  To confirm the correctness 
of the sequence, the peptide with no substitutions and the peptide 
with proline at position 47 replaced by alanine were sequenced on 
a sequencer (477A/120A; Applied Biosystems,  Inc., Foster City, 
CA). The sequences were proven to be correct. All peptides were 
synthesized in the form of amides and had a glycine-glycine-cysteine 
spacer at the COOH terminus. The NH2 terminus of each pep- 
tide was  acetylated. 
Peptides from the sequence of Ib6 were synthesized in the form 
of amides on a peptide synthesizer (9600; MilliGen/Biosearch, Mil- 
ford, MA) using benzotriazolyloxytris (dimethylamino) phospho- 
nium hexafluorophosphate and 1-hydroxybenzotriazole activation 
in a Fmoc-mediated synthesis following Technical Bulletin no. 900- 
03 from Biosearch. Peptide cleavage was accomplished as described 
above. The peptides were precipitated with diethyl ether and lyophi- 
lized. When submitted to reverse-phase chromatography on C18 
columns using a linear gradient as described above, a single major 
absorbance peak at 214 nm was discernible.  The sequence of each 
peptide was confirmed by direct sequencing. 
Immunofluorescence.  Cell-bound human IL-6 was determined by 
indirect  immunofluorescence.  106  CHO  or  CHO-IL-6  cells 
pelleted and prewashed with PBS containing 10 mg/ml BSA (PBS- 
BSA) were mixed with 100 #1 PBS containing 5% normal goat 
serum (PBS-NGS)  and with either control normal mouse IgG or 
with anti-human Ib6 mAb (10/~g in 100/zl; Genzyme, Cambridge, 
MA). After 45 rain at 4~  the cells were washed three times with 
1 ml PBS-BSA. Subsequently,  50/~1 of FITC-labeled goat F(ab')2 
anti-mouse IgG (Tago, Inc., Burlingame, CA), diluted to 3.5/zg/ml 
in PBS-NGS, was added in the dark for 30 min at 4~  The cells 
were washed three times with cold PBS and then resuspended in 
400/~1 of 1% formaldehyde in PBS. Flow cytometry analysis was 
then performed in FACS IV  ~ or FACScan  |  flow cytometers (Becton 
Dickinson Immunocytometry Systems, San Jose, CA). Surface ex- 
pression of I1.-6 on B-IL-6 cells was measured under similar condi- 
tions, except that the cells were preincubated for 30 min at 25~ 
with brefeldin A (4/zg/ml; Boehringer Mannheim Biochemicals, 
Indianapolis, IN) to inhibit secretion of II.,6 (11, 12), and that Graces' 
medium was used instead of PBS-BSA. 
Preparation and Testing of Antit~tide Antisera.  Two NZW rabbits 
were immunized with 200/~g of the respective peptides from IL-6 
(see Fig. 4) in unconjugated form in combination with CFA. The 
rabbits were boosted with 200-/~g doses of peptides in combina- 
tion with IFA in biweekly intervals.  2 wk after each immuniza- 
tion, blood samples  were taken and analyzed for antibodies by 
ELISA. 8-10 wk after the initial immunization, the rabbits were 
killed  after collecting blood by cardiac puncture. 
Wells  of 96-well  polystyrene plates  (Immulon  II;  Dynatech 
Laboratories,  Inc., Chantilly, VA) were coated either with purified 
IL-6 (500 ng/well) produced by CHO-Ib6 cells or with the respec- 
tive synthetic peptides from IL-6 (4/zg/well; 200/zl in 0.1 M Tris, 
pH 8.8) overnight at 20~  The wells were postcoated with BSA 
and gelatin (10 and 2.5 mg/ml, respectively).  Control as well as 
antipeptide antisera were serially diluted (starting dilution, 1:t>20) 
in a mixture of FCS and goat serum (9:1), 0.1% Tween 20, adjusted 
to pH 8.0 (BG). The diluted sera (200/zl) were added to IL-6- or 
peptide-coated wells and incubated overnight at 25~  The wells 
were washed with 0.14 M NaC1, 0.01 M Tris, 0.01% sodium mer- 
thiolate, pH 7.2 (TS). Subsequently, the wells were incubated with 
goat anti-rabbit IgG linked to horseradish peroxidase (Boehringer 
Mannheim Biochemicals)  (diluted 1:1,000 to 1:2,000 in TS con- 
taining 5% normal goat serum and 0.05% Tween 20). After incu- 
bation for 2 h at 37~  the wells were washed with TS, and perox- 
idase activity bound to the wells was determined using a kit from 
Kirkegaard & Perry Laboratories,  Inc.  (Gaithersburg, MD). Ab- 
sorbance at 450 nm was determined in a microplate reader (MR600; 
Dynatech Laboratories,  Inc.).  Dilution endpoints corresponding 
to the highest dilution at which the ratio of absorbance  corre- 
sponding to positive samples divided by absorbance corresponding 
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by Ritchie et al. (15). ELISAs with mouse anti-Ib6 mAbs (Gen- 
zyme, Cambridge, MA) were carried out under similar conditions, 
except that horseradish peroxidase-labeled anti-mouse instead of 
anti-rabbit,  IgG was used. 
Binding of CeUs to Anli-IL.6 Magnetic Beads and to trreS(21-47  ) Cel- 
lulose.  PreS(21-47) cellulose was prepared as described before (1, 
6). Magnetic beads with bound anti-IL-6 mAb were prepared as 
follows: magnetic beads with covalently attached goat anti-mouse 
IgG (300 #1; Advanced Magnetics,  Inc., Cambridge,  MA) were 
mixed with 50/~g of mouse anti-Ib6 mAb overnight at 4~  Un- 
adsorbed antibodies were removed, the beads were washed four 
times with PBS, and resuspended in 300 ~1 of"IS. The attachment 
of HepG2, CHO, CHO-IL-6, and of SD insect cells, either unin- 
fected or infected with wild-type or recombinant  bacnloviruses, 
to preS(21-47) cellulose and anti-IL-6 magnetic beads, respectively, 
was quantitated  as described before (6). In some cases, the cells 
were pretreated with brefeldin A (4/~g/ml) for 30 rain either at 
37~  (CHO-Ib6 cells) or at 25~  (SD cells) to inhibit  secretion 
of Ib6. Conditions for treating cells with PI-PLC or at pH4 were 
the same as already described (6). 
The inhibitory effect of antisera to peptides from IL-6 (final di- 
lution, 1:10) and of peptides from IL-6 and from the preS(21-47) 
sequence (final concentration, 2 mg/ml), respectively,  was followed 
by adding the respective substances to cell-preS(21-47) cellulose 
mixtures,  otherwise following conditions  described above. 
Results 
Expression of  ll.,6 eDNA in Cells Endows Them with Receptors 
for the preSl  Region  of the HBV env Protein.  To determine 
whether or not the biosynthesis of human IL-6, but of no 
other human  gene products,  is sufficient for expression of 
call receptors for the preS(21-47) region of the HBV env pro- 
tein,  cells  transfected with  IL-6 eDNA or infected with  a 
recombinant baculovirus with inserted IL-6 eDNA were as- 
sayed for the presence of HBV receptors.  CHO-IL-6 cells 
secreted  relatively  large  quantities  of Ib6  ('~250  /zg/107 
cells/72 h). SD cells, derived from S. frugiperda ovarian cells, 
infected with recombinant baculovirus carrying IL-6 eDNA, 
produced "~1% of that amount of II.-6. IL-6 was detectable 
on the surface of each of these cell lines by cytofluorometry 
(Fig. 1). Ib6 was not detectable on the surface of CHO cells 
and of uninfected SD cells. 
The  surface expression  of Ib6  on  CHO-II.-6  cells  was 
confirmed by the observation that these cells adsorbed to mag- 
netic beads with attached anti-II.-6  mAbs (Fig. 2 A). CHO- 
II.,6  calls did not bind to control magnetic beads carrying 
normal mouse IgG. Control CHO cells bound to the anti- 
IL-6 beads nonspecifically to a much lesser extent that CHO- 
IL,6  cells.  Pretreatment  of CHO-IL-6  cells  with  PI-PLC 
resulted in their decreased binding to anti-IL-6 beads. Pretreat- 
ment at pH 4 had a minimal effect on the binding of these 
cells to anti-IL-6  beads. CHO-Ib6 calls, unlike CHO cells, 
also bound to preS(21-47) cellulose (Fig. 2 B). Treatment of 
the calls with either PI-PLC or at pH 4 resulted in decreased 
binding to the ceUulose derivative. These results demonstrate 
that surface expression of human IL-6 on calls of nonhuman 
origin  resulted  in  appearance  of  binding  sites  for  the 
preS(21-47) segment of the HBV env protein. CHO-II.-6 ceils 
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Figure  1.  Expression  of" ID6 
on the surface of CHO ceUs  trans- 
fected with Ib6 eDNA and  se- 
creting the IL-6 protein (A), and 
of SD ceUs infected with recom- 
binant baculovirus  carrying  lb6 
eDNA (B). Cells pretreated with 
brefeldin A (4/tg/ml) for 30 rain 
to block secretion of Ib6 (11, 12) 
were reacted with mouse anti-Ib6 
mAb  or  with  control  normal 
mouse  IgG.  Subsequently,  the 
cells were washed and reacted with 
FITC-labded  anti-mouse  IgG. 
The FITC-labeled cells were mea- 
sured by flow cytometry. 
bound also to cellulose with covalently linked hepatitis B sur- 
face antigen (HBsAg) containing the preS1 sequence but not 
to control cellulose with covalently linked BSA or the pep- 
tide preS(12-32)  (data not  shown). 
To confirm that  decreased binding to preS(21-47) cellu- 
lose of CHO-IL-6 cells pretreated with PI-PLC or at pH 4 
can indeed be attributed to release of II.-6 from these cells, 
Ib6 was measured in the supernatant fluids after treating the 
cells. Similar levels of II.-6 were found in cells treated by ei- 
ther method and in mock-treated cells. This was due to con- 
tinued secretion of II-6 from the cells during the 30-rain treat- 
ment period. To block the secretion of IL-6, the cells were 
pretreated with brefeldin A and subsequently exposed to ei- 
ther PI-PLC or to pH 4. Under these conditions, significant 
differences in the release of IL-6 between PI-PLC-, pH 4-, and 
mock-treated cells were observed (Fig. 2 C). Thus, decreased 
binding to preS(21-47) cellulose of PI-PLC- or pH 4-treated 
CHO-IL-6 cells can indeed be explained by the release  of 
surface-bound I1r  from the cells. Treatment  of CHO-IL-6 
cells with brefeldin A did not have any effect on their binding 
to either anti-II.-6 magnetic beads or to preS(21-47) cellulose 
(data not  shown). 
Since transfection  of mammalian  CHO  cells  with  II.-6 
cDNA led to the expression of both II.-6 and of binding sites 
for the HBV env protein,  it  was of interest  to  determine 
whether or not expression of II.-6 in cells phylogenetically 
more distant  from human cells than are CHO cells would 
also lead to appearance of binding sites for the preS region 
of the HBV env protein. Sf9 insect cells infected with recom- 
binant baculovirus carrying II,6 cDNA (B-IL,6 cells) expressed 
on their surface both IL-6 (Fig. 3 A) and HBV receptors (Fig. 
3 B), unlike uninfected cells and cells infected with wild-type 
baculovirus or with recombinant baculovirus carrying eDNA 
for the glucocorticoid binding protein.  Exposure of B-IL-6 
cells to pH 4 or to PI-PLC resulted in the release of Ib6 into 
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Figure  2.  Surface  expression of IL-6 on CHO cells transfected with IL-6 
cDNA and secreting the II.,6 protein  (CHO-IL-6),  and their binding to 
preS(21-47) cellulose. (A) Attachment of control CHO cells and of CHO- 
Ib6 cells that were either mock treated,  exposed to 10 mM citrate, 0.14 
M NaC1, pH 4,  for 5 min at 25=C,  or treated  with PI-PLC  (1 U/ml, 
1 h at 37~  to anti-IL-6 magnetic beads. (B) Attachment of CHO and 
CHO-IL-6 cells (either untreated or treated with PI-PLC or exposed to 
pH 4) to preS(21-47) cellulose. (C) Release of Ib6 from CHO-ID6 cells 
by PI-PI.C or by exposure to pH 4. Cells (106) pretreated  with brefeldin 
A (4 #g/ml) for 30 rain at 37~  were treated for 1 h at 37=C with PI-PI.C 
(100/zl;  1 U/m1 in TS), mock treated  with TS for 1 h at 37~  or in- 
cubated at pH 4 for 5 rain at 25~  ID6 was detected in the supernatant 
fluids after centrifugation of the treated cells. Ib6 was not detectable in 
supernatants  after  treating control CHO calls. 
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Figure 3.  Surface  expression  of ]I-6 on SO cells (derived from S.frugiFenta 
ovarian cells) infected with recombinant  baculovirus carrying 11.-6 cDNA 
(B-IL-6 cells), and their binding to preS(21-47) cellulose. (A) Attachment 
of control uninfected  or wild-type baculovirus-infected  SD cells and of 
B-IL-6 cells that were either mock treated, exposed to 10 mM citrate, 0.14 
M  NaCI, pH 4, for 5 min at 25~  or treated  with PI-PLC  (1 U/m1, 
1 h at 37~  to magnetic anti-IL-6 beads. (B) Attachment of control SD 
and of B-ID6 cells (either untreated  or treated with PI-PLC, or exposed 
to pH 4) to preS(21-47) cellulose. (C) Release of IL-6 from B-Ib6 ceils 
by PI-PI.C  or by exposure to pH 4.  Cells (10  ~) were treated  for 1 h at 
37~  with PI-PLC (100 #1;  1 U/ml in "IS), mock treated  with TS for 
1 h at 37~  or incubated at pH 4 for 5 rain at 25~  Ib6 was determined 
in the supernatant  fluids after centrifugation of the treated cells. I1.-6 was 
not detectable in supernatants  after treating control SD cells. For further 
experimental  details, see legend to Fig. 2. 
the medium (Fig. 3 C) and in diminution of surface-exposed 
I1.-6 and of binding sites for the preS(21-47)  ligand. 
In summary, these results indicate that expression of human 
IL-6 in cells, independent  of their origin, also leads to the 
expression of receptors for the preS1 region of the HBV env 
protein. 
Delineation  of Binding Sites on IL6 for the preS(21-47) Re- 
gion of the HBV env Protein.  Since the preS(21-47)  region 
of the HBV sequence was recognized by IL-6 both in solu- 
tion and in cell-associated form (6), it was of interest to define 
the preS1 binding domain on the Ib6 protein.  To accom- 
plish this, the inhibitory effect of synthetic peptides from the 
IL-6 sequence (Fig. 4), and of the corresponding antipeptide 
antisera on the binding of HepG2 cells to preS(21-47)  cellu- 
lose, was investigated. Synthetic peptides covering the entire 
sequence of IL-6, except the peptide corresponding to the signal 
sequence, reacted with a polyclonal rabbit anti-Ib6 antiserum 
(Fig. 5 A). The antibody dilution endpoint of this antiserum, 
as measured by ELISA on Ib6-coated wells,  was 1:105, i.e., 
~30-fold higher than that obtained with the synthetic pep- 
tides [1-35] and [120-143], respectively, optimally recognized 
by this antiserum. This suggested that the synthetic IL-6 pep- 
tides together did not represent all epitopes exposed on the 
intact II.,6 protein. All peptides from Ib6 were highly im- 
munogenic, and except for the signal peptide  [(-28)-(-1)], 
elicited antibodies recognizing Ib6 (Fig. 5 B). However, the 
titer of antibodies recognizing Ib6 was generally lower than 
that of antibodies reacting with the respective homologous 
peptides, in agreement with the conclusion that the immuno- 
logical crossreactivity between Ib6  and synthetic  peptides 
from Ib6 was partial. 
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Figure 4.  Amino  acid sequence  of IL-6 (/1) (13, 14) and of synthetic 
peptides from II.-6 (B). The peptides are consecutively  numbered from 
I to 8. Amino acids added to either the NHz or COOH termini for ease 
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I1..6 signal sequence. 
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Since the synthetic peptides from Ib6 at least partially mim- 
icked the corresponding  region on the Ib6 protein  at  the 
level of immunological recognition, it was expected that they 
might also be suitable for delineating the preS(21-47) binding 
site within the Ib6 amino acid sequence. Among the 1I:6 
peptides tested for inhibitory activity on the interaction be- 
tween HepG2 cells and preS(21-47) cellulose, peptide [35-66] 
appeared to be the most effective (Fig.  6 A). Peptides [1-35] 
and [90-120] were less effective in this respect. However, on 
molar basis, peptide [35-66] had only ,~1/5,000 of the in- 
hibitory activity of I1:6 (6). All other peptides lacked inhibi- 
tory activity. Reduced and alkylated peptide [35-66] had no 
inhibitory activity, indicating that cysteine residues 44 and 
50 (Fig.  4 A), and possibly a disulfide bond between them, 
were essential for inhibitory  activity. Among the antipep- 
tide antisera tested, only anti-J35-66] significantly inhibited 
the binding of HepG2 cells to preS(21-47) cellulose (Fig. 6 
B). In summary,  assaying of peptides from I1:6 and of the 
corresponding antipeptide antisera for inhibition of binding 
of HepG2 cells to preS(21-47) cellulose suggested that  the 
[35-66] region of the I1:6 sequence overlaps a complemen- 
tary site for the preS(21-47) segment on the HBV env preS1 
sequence. This conclusion was further supported by results 
of epitope mapping of anti-Ib6 mAbs (Fig. 7), shown before 
(6) to inhibit the interaction between the HBV env protein 
and HepG2 cells. 
Identification of Amino Acid Residues within the preS(21-47) 
Sequence Essential for  Recognition by  the  Cell Receptor for 
HBV.  Results of earlier studies identified the preS(21-47) 
segment of the HBV L protein as a binding site for the cell 
receptor for HBV (1).  Results shown above indicated that 
the [35-66]  segment of I1:6 overlaps a complementary site 
for the preS(21-47) sequence. For a better understanding of 
Figure 5.  Andgenicity  and immunogenicity  of synthetic  peptides  from 
the sequence  of Ib6. (A) Serial dilutions of rabbit antiserum against 11.-6 
(having an antibody  dilution endpoint of 1:102,400 as measured  by ELISA 
on IL-6-coated  plates) and a control normal rabbit serum, respectively,  were 
serially diluted in BG and added to wells  of polystyrene  plates coated  with 
peptides covering the entire sequence  of II26 (see Fig. 4). After overnight 
incubation at 20"C, the wells were washed, and rabbit IgG bound to the 
wens was determined by F_LISA  using horseradish peroxidase-hbeled  goat 
anti-rabbit IgG. The dilution endpoints of anti-IL-6, corresponding to 
the highest dilution at which the OD450 readings corresponding to bound 
IgG from the anti-IL-6 serum were  2.1 times higher than that corresponding 
to bound IgG from the control normal rabbit serum, were calculated and 
plotted. (B) Serial dilutions in BG of rabbit antisera against distinct pep- 
tides from the sequence of IL,6 were added to wells coated either with 
the homologous peptides (4 #g/well) or with rIL-6 (500 rig/well). Con- 
trol experiments were carried out with dilutions of normal rabbit serum. 
Antibody dilution endpoints were  determined as described  for A. For fur- 
ther details, see Materials and Methods. 
molecular details of the interaction between the HBV env 
protein and Ib6,  the cell receptor binding site for HBV, it 
was important  to determine which amino acid residues on 
the complementary sequences are essential for the binding 
reaction to occur. Since the mimicry of the preS1 region, in- 
volved in this interaction, by the synthetic peptide preS(21-47) 
was more complete (16) than that of the complementary II.-6 
sequence by the IL-6 peptide [35-66] (Figs. 5 and 6), we decided 
to initiate such studies by first measuring the activity of replace- 
ment  set peptides from the preS(21-47)  sequence.  Alanine 
replacement set peptides corresponding to this sequence were 
synthesized,  and their inhibitory  effect on the attachment 
of HepG2 cells to pre.S(21-47) cellulose was studied. The results 
revealed  that residues 21-25, 28, 31, 34, 35, 39, and 43-45 
could all be replaced by alanine (A), and that the A residue 
at position 33 could be replaced by serine (S) without im- 
pairing the inhibitory activity of the peptides (Fig. 8). All 
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Figure 6.  Inhibition  by synthetic peptides from IL-6 and by the corre- 
sponding antipeptide antisera of attachment of HepG2 cells to preS(21-47) 
cellulose. (,4) The final concentration of each peptide was 2 mg/ml. (B) 
Each antiserum was diluted 10-fold in 0.14 M NaC1, 0.01 M Tris, 0.02% 
NAN3, 1 mM CaC12, pH 7.2 ('IS-CA), containing 10 mg/ml BSA. The 
same diluent was also used for the peptides. The proportion of cells bound 
to preS(21-47) cellulose in the absence of peptides or antipeptide antisera 
ranged between 91 and 97%. 
other replacements,  including substitutions of four proline 
residues at positions 26, 32, 41, and 47, had a deleterious effect. 
Identification of essential amino acid residues within the 
IL-6 sequence, possibly corresponding to contact residues in- 
volved in the IL-6-HBV env protein interaction, will require 
the design of synthetic molecules mimicking the binding site 
for the preS(21-47)  region with greater fidelity  than the 
[35-66] peptide from I1.-6. The design of such mimetics may 
contribute to the development of antiviral agents against HBV. 
Discussion 
Results of earlier studies (6) indicated that: (a) Ib6 in so- 
lution reacted with the L protein constituent of the HBV 
envelope  and  with  synthetic  peptides  preS(12-47)  and 
preS(21-47)  from the preS1 segment of L protein; (b) the 
attachment of HepG2 cells and of other cells expressing a 
receptor for the preS1 region of the HBV env protein with 
immobilized L protein or with preS(21-47) cellulose was in- 
hibited by Ib6 and by anti-Ib6 antibodies; (c) activation of 
T cells and PBMC resulting in biosynthesis of II.-6 also led 
to the expression of receptors for HBV;  and (d) treatment 
of cells expressing receptors for HBV with PI-PLC or their 
brief exposure to pH 4 resulted in release of Ib6 and in de- 
creased binding of the cells to the preSl-specific ligands. These 
results indicated that IL-6 contains recognition sites for the 
preS(21-47) sequence and mediates HBV-ceU interactions, but 
did not establish whether or not other cell surface compo- 
nents were necessary for the association between cells and 
the preS1 region of the HBV env proteins to occur.  Data 
presented here indicate that: (a) the expression of I1,6 in cells 
of nonhuman origin transfected  by human II.-6 eDNA is 
sufficient to endow these cells with receptors recognizing the 
preS(21-47)  segment of the HBV L protein; and (b) other 
cell membrane components are probably not required for this 
recognition. Treatment of the transfected cells with PI-PLC 
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Figure 7.  Epitope mapping of anti-IL-6 mAbs. Anti- 
IL-6 mAbs (100 ng/well), shown to inhibit the binding 
of Ib6 to the preS1 region of the HBV env protein (6), 
were added to wells coated with synthetic peptides from 
IL-6 (500 ng/well). The bound mAbs were determined 
using horseradish  per~idase-hbeled anti-mouse  IgG. The 
OD4s0 values corresponding to control mouse IgG bound 
to the peptide-coated wells were all 0. 
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Figure 8.  Inhibitory effect on the attachment 
of HepG2 cells to preS(21-47) cellulose of replace- 
ment set peptides corresponding to the preS(21-47) 
sequence. The final concentration of each peptide 
was 2 mg/ml. The replacement set consisted of 
peptides  in which  amino acid  residues in the 
preS(21-47) sequence were rephced by alanine (+4). 
Alanines at positions 33 and 36, respectively,  were 
replaced by serines (S). The preS(21-47) sequence 
is presented on top and the replacements are indi- 
cated on the abscissa. The inhibitory effect of the 
parent peptide is presented by the hatched bar. The 
inhibitory effect of the replacement set peptides 
is presented by black bars. The horizontal dashed 
line corresponds to 90% inhibition  of HepG2 cell 
attachment. Amino acid residues, the replacement 
of which led to a decrease of cell attachment inhi- 
bition to <90%, are boxed. 
or their exposure to pH 4 resulted in release of I1:6 and in 
decreased binding activity for the preS(21-47) ligand, as was 
observed earlier with human cells expressing I1"6 either con- 
stitutively or after activation (6). I1:6 released  by PI-PLC from 
HepG2 cells or from I1:6-c-DNA-transfected cells had a mo- 
lecular mass similar to that of I1:6 secreted into the medium 
(23-30 kD), as determined by immunoblotting after elec- 
trophoresis in polyacrylamide gels under reducing and dena- 
turing conditions (our unpublished data), in agreement with 
other reports (17, 18). In addition to ,~27-kD species, less 
abundant larger molecular mass forms of I1:6 ("o47-89 kD) 
were discerned under nondenaturing conditions by molec- 
ular exclusion chromatography on Sephadex G-150 for PI- 
PLC-released I1:6,  as well as for I1:6 secreted either from 
HepG2 cells or from transfected cells (our unpublished data), 
in agreement with results reported by May et al. (17, 19). 
These results suggest that PI-PLC-released I1:6 is predomi- 
nantly not associated with another carrier protein(s) or that 
possible complexes of IL-6 with other proteins are dissociated 
during molecular exclusion chromatography, suggesting a 
weak binding between I1:6 and a putative carrier molecule. 
A possible association between I1-6 and mannose binding pro- 
teins  has  been  recently suggested  (20). The  mechanism 
whereby I1:6 becomes released by PI-PLC from cells remains 
to be elucidated, since the COOH terminus of I1:6 does not 
fulfill the sequence requirements needed for attachment of 
a phosphatidylinositol  glycan (13, 14, 21). 
ri1:6 produced in E.  coli lacking saccharide residues, un- 
like I1-6 from eukaryotic cells (17, 18, 22), also had binding 
sites for the preS(21-47) region of the HBV L protein and 
inhibited the attachment of HepG2 cells to preS(21-47) cel- 
lulose (our unpublished data). This indicated that the binding 
site for the preS(21-47) ligand is located on the protein moiety 
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of Ib6, offering the opportunity to locate this site within 
the II.,6 sequence using synthetic peptides from Ib6. Among 
peptides covering the entire sequence of I1:6 and the corre- 
sponding antipeptide antibodies, peptide [35-66] and the ho- 
mologous anti-J35-66]  antipeptide antiserum were the most 
effective in inhibiting the  attachment of HepG2  cells to 
preS(21-47) cellulose. These results suggest that the [35-66] 
segment of the I1:6 sequence is part of a binding site for the 
preS1 region of the HBV env protein, although other regions 
of the II:6 sequence appear to contribute directly or indirectly 
(through conformational effects) to this binding site. 
Studies with point and deletion mutants of I1:6 and with 
mAbs  of defined  specificity  suggested  that  the  COOH- 
terminal portion of I1:6 encompassing residues [151-183] is 
essential for biological activity and contains the I1:6R binding 
site  (23-26).  On the other hand,  studies  with  NH2-ter- 
minally deleted mutants suggested that residues [29-34] are 
essential for biological activity of I1:6, while residues [1-28] 
could be deleted without affecting activity (27).  Cumula- 
tively,  these  results  suggest  that  both  the  COOH-  and 
NH2-terminal regions are essential for biological activity of 
this cytokine (28). Any internal deletions within the sequence 
of II-6, reported to result in loss of biological activity (28), 
probably prevent the proper folding of I1-6. This agrees with 
the experimentally determined or proposed structures for four 
helix bundle cytokines, including I1:6 (29-33). The binding 
site for the preS(21-47) ligand, tentatively assigned to a re- 
gion of I1-6 encompassing residues [35-66],  is likely to be 
distinct from the I1-6R binding site assigned to residues 
[178-183] (25). The distinctiveness of preS(21-47) and I1"6R 
binding sites is also suggested by the observation  that the 
inhibitory activity of the I1:6 [35-66] peptide on attachment 
of HepG2 cells to the preS(21-47) ligand is abolished after reduction and alkylation of cysteine residues 35 and 50, while 
a mutant II.-6 protein in which all four cysteine residues are 
replaced by serines was reported to retain biological activity 
(34). This raises the possibility of developing antiviral com- 
pounds mimicking the receptor binding site for HBV on Ib6 
but not displaying undesirable biological effects of the intact 
Ib6 molecule.  In this respect, it also appears important  to 
note that: (a) there is no significant sequence homology be- 
tween the preS(21-47) ligand and ID6R (35), and the Ib6 
signal transducer g'p130 (36), respectively; (b) the interaction 
of HepG2 cells and of other cells expressing the receptor for 
the preS1 region of the HBV env protein with the preS(21-47) 
ligand (5) and binding of rlI.,6 to the HBV L protein or to 
the synthetic peptides preS(12--47)  and preS(21--47),  respec- 
tively, required  the presence of Ca  2§  ions (6,  our unpub- 
lished data), while there is so far no evidence that the biolog- 
ical  activity of I1--6 is  manifested  only at  the  presence of 
Ca  2+.  Notwithstanding  the Ca  2  § dependence of the Ib6- 
preS(21-47) association,  consensus sequences characteristic  for 
calcium binding proteins could be recognized on neither the 
I1.-6 or the preS1  sequences. 
Association between Ib6 exposed on the surface of cells 
and the preS1 region of the HBV env L protein is probably 
an important,  but possibly not sufficient, step for entry of 
HBV into cells, resulting in initiation of the virus replication 
cycle.  Additional  cell  receptor  binding  sites  (37,  38)  and 
dividing target cells (39) may be required for virus replica- 
tion.  Transfection of nonhuman  cells with cDNAs coding 
for human cellular proteins may help identify steps required 
for the life cycle of HBV. Cells transfected with human II.-6 
cDNA and expressing receptors for the preS1 region of the 
HBV env protein represent a step towards accomplishing this 
goal. 
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